MicroRNA‑223‑5p suppresses the progression of nasopharyngeal carcinoma by targeting DCLK1

Zhang,Zhixuan; Li,Haifeng; You,Jianqiang; Xue,Haixiang; Tan,Xiaoye; Chao,Changjiang

doi:10.3892/ol.2021.12657

MicroRNA‑223‑5p suppresses the progression of nasopharyngeal carcinoma by targeting DCLK1

Authors:
- Zhixuan Zhang
- Haifeng Li
- Jianqiang You
- Haixiang Xue
- Xiaoye Tan
- Changjiang Chao
View Affiliations

Affiliations: Department of Otorhinolaryngology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China
Published online on: March 18, 2021 https://doi.org/10.3892/ol.2021.12657
Article Number: 396
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the function of microRNA (miR)‑223‑5p in the malignant biological behavior of nasopharyngeal carcinoma (NPC) and elucidate the underlying molecular mechanism. The expression levels of miR‑223‑5p and doublecortin‑like kinase 1 (DCLK1) were detected via reverse transcription‑quantitative PCR analysis. Cell viability was evaluated using Cell Counting Kit‑8 assay. Cell migration and invasion were measured via Transwell assays, while a luciferase reporter assay was conducted to identify the interaction between miR‑223‑5p and DCLK1. The results demonstrated that miR‑223‑5p expression was significantly downregulated, whereas DCLK1 expression was significantly upregulated in NPC tissues and cells. Moreover, both miR‑223‑5p overexpression and DCLK1 silencing markedly suppressed the progression of NPC. It was also observed that miR‑223‑5p directly targeted DCLK1 and decreased its expression. Furthermore, it was suggested that DCLK1 overexpression may partially reverse the suppressive effects of miR‑223‑5p on the progression of NPC. Collectively, the results of the present study indicated that miR‑223‑5p may suppress NPC progression by targeting DCLK1, thereby indicating a novel potential approach to the diagnosis and treatment of NPC.

View Figures

View References

1	Cao SM, Simons MJ and Qian CN: The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 30:114–119. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lee VH, Lam KO, Chang AT, Lam TC, Chiang CL, So TH, Choi CW and Lee AW: Management of nasopharyngeal carcinoma: Is adjuvant therapy needed? J Oncol Pract. 14:594–602. 2018. View Article : Google Scholar : PubMed/NCBI
3	Wang TT, Chen ZZ, Xie P, Zhang WJ, Du MY, Liu YT, Zhu HY and Guo YS: Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma. Eur J Pharmacol. 856:1723522019. View Article : Google Scholar : PubMed/NCBI
4	Yi SJ, Liu P, Chen BL, Ou-Yang L, Xiong WM and Su JP: Circulating miR-31-5p may be a potential diagnostic biomarker in nasopharyngeal carcinoma. Neoplasma. 66:825–829. 2019. View Article : Google Scholar : PubMed/NCBI
5	Genova P, Brunetti F, Bequignon E, Landi F, Lizzi V, Esposito F, Charpy C, Calderaro J, Azoulay D and deAngelis N: Solitary splenic metastasis from nasopharyngeal carcinoma: A case report and systematic review of the literature. World J Surg Oncol. 14:1842016. View Article : Google Scholar : PubMed/NCBI
6	Venkatadri R, Muni T, Iyer AK, Yakisich JS and Azad N: Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death. Cell Death Dis. 7:e21042016. View Article : Google Scholar : PubMed/NCBI
7	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
8	Dou L, Han K, Xiao M and Lv F: miR-223-5p suppresses tumor growth and metastasis in non-small cell lung cancer by targeting E2F8. Oncol Res. 27:261–268. 2019. View Article : Google Scholar : PubMed/NCBI
9	Wei Y, Peng J, He S, Huang H, Lin L, Zhu Q, Ye L, Li T, Zhang X, Gao Y and Zheng X: miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration. J Cancer. 11:4453–4463. 2020. View Article : Google Scholar : PubMed/NCBI
10	Sugawara S, Yamada Y, Arai T, Okato A, Idichi T, Kato M, Koshizuka K, Ichikawa T and Seki N: Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: Targeted genes are involved in bladder cancer pathogenesis. J Hum Genet. 63:657–668. 2018. View Article : Google Scholar : PubMed/NCBI
11	Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J, et al: Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 16:635–643. 2020. View Article : Google Scholar : PubMed/NCBI
12	Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG and Houchen CW: DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One. 8:e739402013. View Article : Google Scholar : PubMed/NCBI
13	Shan C, Fei F, Li F, Zhuang B, Zheng Y, Wan Y and Chen J: miR-448 is a novel prognostic factor of lung squamous cell carcinoma and regulates cells growth and metastasis by targeting DCLK1. Biomed Pharmacother. 89:1227–1234. 2017. View Article : Google Scholar : PubMed/NCBI
14	Liang H, Yu T, Han Y, Jiang H, Wang C, You T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 17:1192018. View Article : Google Scholar : PubMed/NCBI
15	Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, et al: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 16:302017. View Article : Google Scholar : PubMed/NCBI
16	Wang J, Wang S, Zhou J and Qian Q: miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer. Biomed Pharmacother. 102:147–152. 2018. View Article : Google Scholar : PubMed/NCBI
17	Mohammadi Y, Tavangar SM, Saidijam M, Amini R, Etemadi K, Karimi Dermani F and Najafi R: DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. Biomed Pharmacother. 103:301–307. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ and Lu NH: Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: A novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol. 37:72–79. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu H, Wen T, Zhou Y, Fan X, Du T, Gao T, Li L, Liu J, Yang L, Yao J, et al: DCLK1 plays a metastatic-promoting role in human breast cancer cells. Biomed Res Int. 2019:10619792019.PubMed/NCBI
21	Liu W, Wang S, Sun Q, Yang Z, Liu M and Tang H: DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer. Int J Cancer. 142:2068–2079. 2018. View Article : Google Scholar : PubMed/NCBI
22	Liu ZQ, He WF, Wu YJ, Zhao SL, Wang L, Ouyang YY and Tang SY: LncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axis. BMC Gastroenterol. 20:1562020. View Article : Google Scholar : PubMed/NCBI
23	Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019. View Article : Google Scholar : PubMed/NCBI
24	Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, et al: miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci. 124:2997–3005. 2011. View Article : Google Scholar : PubMed/NCBI
25	Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 71:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
26	Li Y, He Q, Wen X, Hong X, Yang X, Tang X, Zhang P, Lei Y, Sun Y, Zhang J, et al: EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma. Cell Death Differ. 26:1089–1106. 2019. View Article : Google Scholar : PubMed/NCBI
27	Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and Wong N: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa T and Seki N: Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci. 107:84–94. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yang W, Lan X, Li D, Li T and Lu S: MiR-223 targeting MAFB suppresses proliferation and migration of nasopharyngeal carcinoma cells. BMC Cancer. 15:4612015. View Article : Google Scholar : PubMed/NCBI
30	Wang W, Zhang H, Wang L, Zhang S and Tang M: miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1. Biochem Biophys Res Commun. 473:987–992. 2016. View Article : Google Scholar : PubMed/NCBI
31	Sakaguchi M, Hisamori S, Oshima N, Sato F, Shimono Y and Sakai Y: miR-137 regulates the tumorigenicity of colon cancer stem cells through the inhibition of DCLK1. Mol Cancer Res. 14:354–362. 2016. View Article : Google Scholar : PubMed/NCBI
32	Wan MF, Yang N, Qu NY, Pan YY, Shan YQ and Li P: MiR-424 suppressed viability and invasion by targeting to the DCLK1 in neuroblastoma. Eur Rev Med Pharmacol Sci. 24:5526–5533. 2020.PubMed/NCBI
33	Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, et al: Dominant expression of DCLK1 in human pancreatic cancer stem cells accelerates tumor invasion and metastasis. PLoS One. 11:e01465642016. View Article : Google Scholar : PubMed/NCBI
34	Wang YL, Li Y, Ma YG and Wu WY: DCLK1 promotes malignant progression of breast cancer by regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 23:9489–9498. 2019.PubMed/NCBI
35	Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS and Wu K: Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Lett. 369:20–27. 2015. View Article : Google Scholar : PubMed/NCBI